Territories of Excellence
The Eurobiomed rationale is to leverage the tremendous scientific and economic potential existing in its territory.
To make its action more effective, Eurobiomed has identified the main areas of expertise and has defined business lines that seem both promising in terms of development and are positioned in differentiated time horizons with a view to risk management. Eurobiomed focuses its resources on projects with high-added value, with the ambition to contribute to addressing the major health challenges of tomorrow.
In this spirit, Eurobiomed undertakes, alongside the different regional actors, the creation, animation and support of strategic initiatives:
MI is a single cluster in the world, both by its vocation as its mission. The result of 40 years of discoveries and innovations in immunology, MI is now exclusively dedicated to fundamental and applied immunology.
Its goal: to accelerate the discovery and development of novel immunotherapies against cancers and inflammatory diseases and ensure that patients benefit rapidly from these innovations.
MI brings together more than 40 businesses, including Innate Pharma, academic and clinical research laboratories, the University of Aix Marseille and AP-HM.
Marseille Immunopôle is certified as a project of the new Industrial France and has the status of university hospital department
The actors of medical diagnosis are brought together at Euromediag. In 2010, Eurobiomed initiated the deployment of actions dedicated to this sector, which was emerging at the time, after measuring the extensive network present in the territory including the number of businesses and the research force. Indeed, more than 70 structures are directly involved in diagnosis innovation development, which pulls in the most significant actors in Europe! The challenge is therefore to strengthen this position as a European leader by strengthening synergies in support of excellence initiatives, collaborative projects, developing a dense network of international partnerships in order to strengthen the country's leading position and the cluster’s businesses.
Euromediag is the founder and leader of the first global cluster in the field of diagnosis: EDCA European Diagnostic Cluster Alliance. It is currently composed of 450 in vitro diagnosis businesses.
Rare is the reference event for rare diseases in France. It is organised by Eurobiomed and takes place every two years in Montpellier, bringing together all stakeholders.
Through conferences, roundtables, workshops, scientific presentations, Rare reports on treatment advances, regulatory issues and societal issues of patient care. Rare provides the opportunity for business to meet in the presence of numerous specialised businesses.
OPHTA BIOTECH is an initiative and collaborative platform unique to Europe, serving visually impaired patients. Supported by Eurobiomed, Horus Pharma co-founded and chairs Ophta Biotech, an association uniting key Ophthalmology players in the Mediterranean arc.
Co-founded in 2009 by Claude Claret (Horus Pharma), Pierre-Paul Elena (Iris Pharma), Pr. Pierre Gastaud (CHU de Nice) and Dr. Loïc Lozivit (ophthalmologist, Nice), the Ophta Biotech association brings together key players in diagnosis, therapy and ophthalmology research, around patient associations in the Mediterranean arc.
Based on the pooling of multidisciplinary skills and dialogue with patients, Ophta Biotech promotes emergence of new projects and tools at the service of the visually impaired. The association:
- Shares the latest technological, therapeutic and societal innovations during annual Low Vision conferences for specialists as well as for patients
- Activates synergies between researchers, practitioners, industry and associations of the visually impaired
- Evaluates and supports research projects in ophthalmology, submitted by researchers and start-ups specializing in biotechnology.
Mediterrannée Infection Foundation aims to condense the means to fight against infectious diseases that are the leading cause of death worldwide (17 million deaths per year) and especially the three global killers (HIV, tuberculosis and malaria) in a major and strategic local, national and international cluster.
Kyomed is a company created in 2014, following the CR2i DiagnoSTIC Santé project. This project, led by Eurobiomed, was awarded the Future Investment Programme "Strategic Industrial Sectors" in December 2013.
The company supports its customers in developing their innovative healthcare solutions in the field of e-health and personalised medicine, from the research stage to marketing. Its services are based on three technological platforms:
- a living lab (evaluation board and co-designing health solutions);
- an identification and biomarker development platform; and
- an IT platform for the analysis, treatment and management of health-related data.